Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
Michael G Oefelein Clinical Trials ( Site 0005), Bakersfield, California Carolina Urologic Research Center ( Site 0006), Myrtle Beach, South Carolina Austria
Medizinische Universität Wien ( Site 0021), Vienna, State of Vienna Belgium
UZ Gent ( Site 0031), Ghent, Oost-Vlaanderen Canada
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011), Québec, Quebec Greece
European Interbalkan Medical Center ( Site 0051), Thessaloniki Israel
Rabin Medical Center ( Site 0062), Petah Tikva Netherlands
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 0081), Amsterdam, North Holland Norway
Akershus Universitetssykehus ( Site 0091), Lorenskog, Akershus Spain
Hospital Universitario Virgen de la Victoria ( Site 0111), Málaga, Andalusia Hospital Universitario 12 de Octubre ( Site 0112), Madrid, Madrid, Comunidad de Turkey (Türkiye)
Ankara University Health Practice and Research Hospitals ( Site 0132), Ankara